ArticleDiabetic medicine : a journal of the British Diabetic Association2018
Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA
Article in Diabetic medicine : a journal of the British Diabetic Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Glycemic Targets.Hormone research in paediatrics · 2024Guideline
- Cost-Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic Countries.Diabetes, obesity & metabolism · 2026Article
- Real-world experience with insulin glargine U300 in pediatric type 1 diabetes: glycemic control, insulin requirements, and patient-reported outcomes.BMC endocrine disorders · 2026Observational
- A biobehavioural and social-structural model of inflammation and executive function in pediatric chronic health conditions.Health psychology review · 2024Article
- Pharmacoeconomic evaluation of insulin aspart and glargine in type 1 and 2 diabetes mellitus in Iran.Journal of diabetes and metabolic disorders · 2023Article
- Healthcare resource utilization and cost among patients with type 1 diabetes in the United States.Journal of managed care & specialty pharmacy · 2020Observational
- Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbADiabetic medicine : a journal of the British Diabetic Association · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsInsulin therapy is indicated for people with Type 1 diabetes mellitus; however, treatment-related weight gain and hypoglycaemia represent barriers to optimal glycaemic management. This study assessed the health economic value of maintained reductions in HbA
methodsThe Cardiff Type 1 Diabetes Model was used to estimate lifetime costs, life-years and quality-adjusted life-years (QALYs) for individuals with Type 1 diabetes at different baseline HbA
resultsModelled subjects with an HbA
conclusionsMaintained reductions in HbA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.